CG Results Healthcare advised Ajinomoto Bio-Pharma Services on the licencing of its Crystalomics Formulation Technology to Kyowa Kirin
- Service: Licensing
- Sector: Healthcare
- Sub Sector: Pharma & Biotech
- Engagement Type: Sell Side
Mar 2021
has licensed the patents and know-how to its Crystalomics Formulation Technology to
Deal Team
Sector Related Deals
May 2022
A subsidiary of Servier
has divested its anti-LAG-3 monoclonal antibody to
A subsidiary of Sino Biopharmaceutical Limited
Mar 2022
has divested its Ringaskiddy, Ireland, manufacturing facility
Mar 2022
has divested its Boucherville, Canada manufacturing facility
Jan 2022
has divested its API manufacturing site in Cramlington, UK, to
Nov 2021
has invested in
company name confidential
Jun 2021
has acquired a drug product manufacturing facility from
May 2021
has formed a strategic alliance with
Jan 2021
has divested its Mirabel manufacturing site in Riom, France to
Jan 2021
has divested its Ringaskiddy analytics and testing site to
